Abstract
Background As gene-specific therapy for inherited retinal dystrophy (IRD) advances, unified variant interpretation across institutes is becoming increasingly important. This study aims to update the genetic findings of 86 retinitis pigmentosa (RP)–related genes in a large number of Japanese RP patients by applying the standardized variant interpretation guidelines for Japanese IRD patients (J-IRD-VI guidelines) built upon ACMG/AMP rules and assess the contribution of these genes in RP-allied diseases.
Methods We assessed 2325 probands with RP (n=2155, including n=1204 sequenced previously with the same sequencing panel) and allied diseases (n=170, all newly analyzed), including Usher syndrome, Leber congenital amaurosis, and cone-rod dystrophy (CRD). Target sequencing using a panel of 86 genes was performed. The variants were interpreted according to the J-IRD-VI guidelines.
Results A total of 3564 variants were detected, of which 524 variants were interpreted as pathogenic or likely pathogenic. Among these 524 variants, 280 (53.4%) had been either undetected or interpreted as variants of unknown significance or benign variants in our earlier study of 1204 RP patients. This led to a genetic diagnostic rate in 38.6% of RP patients, with EYS accounting for 46.7% of the genetically solved patients, showing a 9% increase in diagnostic rate from our earlier study. The genetic diagnostic rate for CRD patients was 28.2%, with RP-related genes significantly contributing over other allied diseases.
Conclusion A large-scale genetic analysis using the J-IRD-VI guidelines highlighted the unique genetic findings for Japanese IRD patients; these findings serve as a foundation for the clinical application of gene-specific therapies.
Competing Interest Statement
KMN reports grants from JCR Pharmaceuticals Co., Ltd., Sysmex Inc., and Novartis Pharma Co., Ltd., consulting fees from Sysmex Inc. and Novartis Pharma Co., Ltd., and Lecture fees from Sysmex Inc., Novartis Pharma Co., Ltd. and Janssen Co., Ltd.. KMN has patents related to gene therapy for retinitis pigmentosa. In addition, KMN is an advisory board member of Sysmex Inc. and Novartis Pharma Co., Ltd..
Funding Statement
The study was supported by the Japan Retinitis Pigmentosa Registry Project and grants from Japan Agency for Medical Research and Development (23ek0109632 to YI, 23ym0126071h0002 and 23ek0109660h0001 to KMN), Japan Society for the Promotion of Science (20K23005 and 22K16969 to YK, 22K09831 to SU, 21K09756 to THa, 22K09825 to KK, and 23H03059 to KMN), Japanese Retinitis Pigmentosa Society (JRPS) Research Grant to YK, and Takayanagi Retina Research Award to YK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants were recruited at Nagoya University Hospital, Kyushu University Hospital, Tohoku University Hospital, Yuko Wada Eye Clinic, Kindai University Hospital, University of Miyazaki Hospital and Miyata Eye Hospital, Juntendo University Hospital, The Jikei University Hospital, and Hamamatsu University Hospital. Ethics committee of all the hospitals gave ethical approval for this work. Written informed consent was obtained from all subjects prior to participation in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data relevant to the study are included in the article or uploaded as supplementary information.
